1. Home
  2. CRSP vs ACLS Comparison

CRSP vs ACLS Comparison

Compare CRSP & ACLS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

CRSP

CRISPR Therapeutics AG

HOLD

Current Price

$51.20

Market Cap

5.0B

Sector

Health Care

ML Signal

HOLD

Logo Axcelis Technologies Inc.

ACLS

Axcelis Technologies Inc.

HOLD

Current Price

$144.16

Market Cap

5.8B

Sector

Technology

ML Signal

HOLD

Company Overview

Basic Information
Metric
CRSP
ACLS
Founded
2013
1995
Country
Switzerland
United States
Employees
393
N/A
Industry
Biotechnology: Biological Products (No Diagnostic Substances)
Industrial Machinery/Components
Sector
Health Care
Technology
Exchange
Nasdaq
Nasdaq
Market Cap
5.0B
5.8B
IPO Year
2016
2000

Fundamental Metrics

Financial Performance
Metric
CRSP
ACLS
Price
$51.20
$144.16
Analyst Decision
Buy
Buy
Analyst Count
17
4
Target Price
$70.29
$101.50
AVG Volume (30 Days)
1.6M
559.0K
Earning Date
05-11-2026
05-07-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
0.30
Revenue
$289,590,000.00
$839,048,000.00
Revenue This Year
$807.72
$1.93
Revenue Next Year
$172.52
$7.91
P/E Ratio
N/A
$472.90
Revenue Growth
9169.85
N/A
52 Week Low
$44.12
$65.64
52 Week High
$78.48
$193.78

Technical Indicators

Market Signals
Indicator
CRSP
ACLS
Relative Strength Index (RSI) 42.57 44.54
Support Level $47.92 $130.15
Resistance Level $59.61 $147.94
Average True Range (ATR) 3.39 11.03
MACD -0.83 -3.20
Stochastic Oscillator 12.78 31.93

Price Performance

Historical Comparison
CRSP
ACLS

About CRSP CRISPR Therapeutics AG

Crispr Therapeutics is a gene editing company focused on the development of Crispr/Cas9-based therapeutics. Crispr/Cas9 stands for clustered regularly interspaced short palindromic repeats (Crispr)/Crispr-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. Crispr's first approved drug is Casgevy, which was developed in collaboration with Vertex Pharmaceuticals and targets sickle-cell disease and transfusion-dependent beta-thalassemia. The company is advancing a variety of gene editing programs in immuno-oncology, cardiovascular, and a stem cell-derived therapy to treat Type 1 diabetes.

About ACLS Axcelis Technologies Inc.

Axcelis Technologies Inc designs, manufactures, and services ion implantation and other processing equipment used in the fabrication of semiconductor chips. In addition to equipment, the company provides aftermarket lifecycle products and services, including used tools, spare parts, equipment upgrades, maintenance services, and customer training. Geographically, the group has a business presence in North America, Asia Pacific, and Europe, of which key revenue is derived from the Asia Pacific.

Share on Social Networks: